The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa ( 
130 000 women in the USA will be diagnosed with ovarian cancer and more than 75 000 will die from their disease. 2 At diagnosis, 75 to 85% of patients have advanced stage III or IV disease, 3 with a 5-year survival with conventional therapy of only 15-25% for stage III and less than 5% for stage IV disease. 4 Clearly, there is a need for more effective therapy for this disease.
Early trials of high-dose chemotherapy (HDC) with autologous stem cell rescue demonstrated initial high response rates for patients with relapsed ovarian cancer both for single agents and chemotherapy combinations. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Patients treated had usually failed at least two prior regimens and had developed progressive disease either during or within 6 months of achieving a remission with platinum therapy. Although initial response rates of 55-75% have been reported, remission durations were consistently short-lived, usually only 5-7 months.
Because long-term event-free survival has been seen in only 5-25% of all ovarian cancer patients treated with HDC regimens, there is a need to improve the conditioning regimen. A conditioning regimen of busulfan, melphalan and thiotepa (BUMELTT) was developed in a phase I clinical trial at Fred Hutchinson Cancer Research Center (FHCRC). These three drugs were selected because they can be administered in an outpatient setting and they have demonstrable activity against adenocarcinoma, including breast [15] [16] [17] [18] [19] [20] and ovarian cancer. 7, 9, 10, 15, 18, 20, 21 Finally, their dose-limiting toxicity is marrow ablation which is easily resolved by the infusion of PBSC. In the phase I clinical trial, the maximum tolerated dose of TT was 500 mg/m 2 , when given with a fixed dose of 12 mg/kg BU and 100 mg/m 2 MEL. 20 This report presents the results of BUMELTT followed by autologous PBSC rescue in treating patients with advanced stage III/IV ovarian cancer.
Patients and methods
Between 9 February 1994 and 2 April 1996, 31 patients with advanced ovarian cancer (15 patients in clinical CR and 16 patients with persistent disease) were treated with BUMELTT, followed by autologous PBSC infusion.
Patients were eligible for this protocol if they had a bilirubin Ͻ2 mg/dl, a creatinine clearance 50 mg/min and a Karnofsky score у70. Ten patients were treated at FHCRC or Oregon Health Sciences Center, Portland, OR, USA and 21 patients were treated at seven participating community cancer centers under the auspices of the Puget Sound Oncology Consortium. Signed consent was obtained from all patients to be treated on the FHCRC or Puget Sound Oncology Consortium protocol which was approved by the Institutional Review Board of the hospital where the therapy was administered.
Definitions
Patients who relapsed within 6 months of completing platinum-based chemotherapy or whose disease progressed on platinum-based therapy were classified as platinum-resistant. Patients who relapsed longer than 6 months from completion of platinum-based therapy were classified as platinum-sensitive.
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Patients were staged non-surgically prior to the administration of chemotherapy for mobilization of PBSC. Complete baseline staging included CT of the abdomen and pelvis, chest X-ray, bone marrow aspirate/biopsy and CA125 blood test. For purposes of measuring response to HDC, restaging was carried out within 6 weeks of HDC.
Patients with clinical CR had no evidence of disease by physical examination, radiographic evaluation or an elevated CA125 blood test. Fifteen patients were in clinical CR entering HDC and consequently were not evaluated for initial response to therapy but were evaluated for survival and time to relapse. Sixteen patients had clinical evidence of disease at HDC and these patients were available for evaluation for initial response to the HDC. Bulky disease at HDC was defined as у1 cm of measurable tumor at transplant.
Duration of response was calculated from day of PBSC infusion (day 0). Responses for patients with detectable and measurable disease were defined as CR if there was a complete disappearance of all tumor and normalization of CA125 for a minimum of 30 days. Partial remission (PR) was defined as a reduction of 50% or more in all measurable disease including CA125 levels for at least 30 days. Responses of less than 50% or progression of disease were considered as no response (NR). All patients were restaged at sites of prior disease at 60-85 days and yearly after HDC.
Neutrophil engraftment was defined as the first day on which the absolute neutrophil count (ANC) exceeded 0.5 × 10 9 /l following the nadir (for 3 consecutive days). Platelet transfusion independence was defined as the first day on which the platelet count exceeded 20 × 10 9 /l without transfusion for 7 consecutive days.
Regimen-related toxicity grading
Regimen-related toxicities (RRT) were graded to day 100 following PBSC infusion using a previously described grading system. 20, 21 Toxicities of the oral cavity, skin and renal, hepatic, cardiac, pulmonary, gastrointestinal, urological and neurological systems were assessed. Venoocclusive disease of the liver (VOD) was defined clinically by hepatomegaly, liver tenderness, weight gain Ͼ2% of baseline and an elevated serum bilirubin Ͼ2 mg/dl, and histologically by damaged endothelial cells of the terminal hepatic venules, dilation of the sinusoids and necrosis of hepatocytes. 22 Idiopathic pneumonia syndrome (IPS) was defined as pulmonary infiltrates not associated with pulmonary edema or an identifiable infectious agent. 23 The incidence of infection is excluded from this grading system and is reported separately. Complete toxicity grading was available on all 31 patients. /kg (range 2.85-94.66). Techniques for collecting PBSC, cryopreserving, thawing and reinfusing PBSC have been previously reported. 24, 25 Nineteen patients proceeded immediately to HDC after collection of PBSC. The other patients received additional chemotherapy (adriamycin/taxol, one cycle and VP16, one cycle (n = 1), cytoxan/VP16, one cycle (n = 2), cytoxan/carboplatinum (CBDCA)/VP16, two cycles (n = 1), taxol, two cycles (n = 2), cytoxan/VP16/cisplatinum (CDDP), one cycle (n = 3), cytoxan/taxol, two cycles (n = 2), taxol/carboplatinum, two cycles (n = 1)) before HDC.
HDC treatment regimen and PBSC infusion
Patients were treated with phenytoin beginning 24 h prior to the first dose of BU and continuing until 24 h after the last dose. All patients received BU at 1 mg/kg/dose orally every 6 h for 12 doses (total dose of 12 mg/kg) on days Ϫ8, Ϫ7 and Ϫ6. MEL at 50 mg/m 2 was given intravenously on days Ϫ5 and Ϫ4, for a total dose of 100 mg/m 2 . TT at a dose of 250 mg/m 2 was administered intravenously on days Ϫ3 and Ϫ2, for a total dose of 500 mg/m 2 . PBSC were thawed and infused 36 h after the last dose of TT on day 0.
Supportive care
Following the administration of the HDC treatment regimen, patients received prophylactic antibiotics when their absolute neutrophil count (ANC) was Ͻ0.5 × 10 9 cells/l. Patients who were positive by serology for herpes simplex virus prior to HDC received prophylactic acyclovoir. All patients received anti-fungal prophylaxis with fluconazole from day Ϫ8 to day +75 post-PBSC infusion. PCP prophylaxis was administered through conditioning, discontinued 48 h before PBSC infusion and resumed after evidence of engraftment to day +180 following PBSC infusion. Eight patients also received G-CSF at 5 g/kg/day beginning after the infusion of PBSC and continuing until engraftment of neutrophils. Patients received irradiated blood products from the appropriate CMV status donors according to the guidelines of their respective institution.
Statistics
Actuarial probabilities of OS and EFS were computed according to the method of Kaplan and Meier. 26 Survival was calculated from the time of PBSC infusion until death or date of last contact. The end-points for EFS were death or relapse. Relapse (R) was estimated by the method of cumulative incidence. 27 Patients not achieving CR or PR were considered to have relapsed on day 1 following PBSC infusion. Patients who achieved a PR after HDC were considered to have relapsed at the first documentation of progression of disease. Patients who died within 100 days after PBSC infusion were categorized as dying from transplantrelated toxicities. Patients who died after day 100 with evidence of recurrent or persistent disease were categorized as dying from relapse, irrespective of actual cause of death. The date of last contact with surviving patients was 8 August 1997. The median follow-up of all patients who survived beyond day 100 following PBSC infusion was 564 days.
Results

Patient characteristics (Table 1)
Of the 31 patients, one patient had stage I disease at diagnosis, three had stage II, 21 had stage III/IIIc and six had stage IV. The predominant pathology of these patients at diagnosis was serous adenocarcinoma. The median number of cycles of conventional chemotherapy these patients received prior to mobilization and collection of PBSC was 11 (range 6-36 cycles). The median number of different regimens prior to mobilization was three (range 1-6). One patient also received abdominal radiation and nine patients received intraperitoneal chemotherapy. The median time from initial diagnosis to HDC was 640 days (range 237-2205 days) and the median age at HDC was 47 years (range 39-63 years). At HDC, 18 patients had stage III/IIIc and 13 had stage IV disease.
Of the 15 patients with no clinical evidence of disease at HDC; seven were in first clinical CR, seven in second clinical CR and one in third clinical CR. The treatment histories of the seven patients in first clinical CR are outlined in Table 2 . Three of the seven patients received intraperitoneal therapy. The number of different regimens these first clinical CR patients received was from two to four, including mobilization chemotherapy and the number of cycles of chemotherapy was from six to 12. Only one patient (No. 6) had documented pathological complete remission at second look after intraperitoneal therapy. One patient (No. 2) was treated with five cycles of conventional taxol/CBDCA and the mobilization chemotherapy regimen. Eleven patients out of the 15 had platinum-sensitive disease at the time of HDC. Of the 16 patients with persistent disease at HDC: four had primary persistent disease, 11 were in first relapse and one was in third relapse. Only two had platinum-sensitive disease.
Nine patients had bulky disease at HDC. One patient with bulky disease died of RRT. Four patients had no response to HDC. Three patients entered clinical CR after HDC but relapsed at day 107, 160 and 220. One patient had a PR to HDC and her disease progressed on day 429.
Compliance with HDC
All patients received the prescribed doses of the HDC regimen, BUMELTT.
PBSC infusion and engraftment
The median number of PBSC infused was 9.41 ϫ 10 
Regimen-related toxicities (RRT) and transplant-related mortality
Grade 1-2 toxicities were common. All patients developed grade 2 stomatitis, 6.5% developed grade 1-2 cardiac toxicity, 12.9% grade 1-2 pulmonary toxicity, 77.4% grade 1-2 colitis, 45.2% grade 1-2 skin toxicity, 6.5% grade 1-2 neurological toxicity, 6.5% grade 1-2 bladder toxicity, 3.2% grade 1-2 renal insufficiency and 29.0% grade 1-2 hepatic toxicity.
Grade 3-4 toxicities occurred in four patients (12.9%). One patient developed grade 4 veno-occlusive disease (VOD), two patients developed grade 3 colitis and one patient developed not only grade 4 pulmonary toxicity but also grade 3 stomatitis and grade 3 skin toxicity. Two of the patients (6.5% of all patients) died from RRT: one death was due to pulmonary complications and occurred in an individual who had no evidence of disease at the initiation of HDC and the other death was due to VOD and occurred in a patient with persistent disease in the liver at the initiation of HDC. Both deaths occurred in patients with platinum-resistant disease.
In addition, seven patients (22.6%) developed positive bacterial or fungal blood cultures, but none died of infection.
Response
Sixteen patients were not evaluable for the initial response to HDC due to early death (n = 2) or lack of detectable disease at initiation of the HDC regimen (n = 14). Six out of the 15 patients (40.0%) with persistent disease at the initiation of HDC had no response to the conditioning regimen. Five patients (33.3%) achieved a CR, of whom two had platinum-sensitive disease. Four out of 15 patients had a PR (26.7%). The total CR and PR response to BUMELTT in evaluated patients was 60%.
The actuarial probabilities of OS, EFS and R for all patients at 18 months were 0.57, 0.30 and 0.63 (Figure 1a  and b) .
Fifteen patients were treated with HDC at a time of clinical complete remission. The actuarial probabilities of OS, EFS and R for these patients at 18 months were 0.87, 0.44 and 0.49 (Figure 2a and b) . One patient died of pulmonary complications on day 34. Seven patients remain alive and in remission. Five patients relapsed at days 129, 133, 155, 348 and 614 after HDC and are still alive. Two patients who relapsed at 160 and 379 days succumbed to their disease on days 171 and 875, respectively. Of the seven patients who were in first clinical CR at the time of HDC, Sixteen patients with persistent disease were treated with BUMELTT. The actuarial probabilities of OS, EFS and R in these patients at 18 months were 0.38, 0.13 and 0.81 (Figure 3a and b) . One patient died of RRT secondary to VOD on day 56. The other patients died from relapse on days 139, 250, 320, 359, 418, 429, 422 and 520 days following PBSC infusion. Only one patient with platinumresistant disease and in first relapse at HDC remains alive and in remission at 579 days. This patient alone received taxol/adriamycin and high-dose etoposide therapy prior to HDC.
Of the 13 patients with platinum-sensitive disease, none died of RRT. All patients remain alive and seven patients have relapsed at 129-1021 days. Four of the six patients that remain alive without evidence of disease were transplanted in 1st clinical CR. The OS, EFS and R rates for these patients at 18 months were 1.00, 0.52 and 0.48 (Figure 4a and b) .
Of the 18 patients with platinum-resistant disease, two died of RRT. Six patients did not respond to the HDC. Eight additional patients have relapsed between days 104-429. Four patients remain alive and two of these four (transplanted in 1st relapse and 2nd CR) are still in remission at 579 and 736 days after HDC. The OS, EFS and R rates at 18 months were 0.33, 0.11 and 0.78 (Figure  5a and b) . 
Discussion
A regimen of HDC with BUMELTT followed by autologous PBSC rescue was administered to 31 patients with advanced stage III/IV ovarian cancer. Death due to complications of the HDC occurred in 6.5% of the patients. Not surprisingly the overall and event-free survivals were superior for patients transplanted in clinical CR who had mainly platinum-sensitive disease. Although these results are encouraging, follow-up is still relatively short. The ultimate number of patients who will be long-term disease-free survivors remains to be determined. Overall, the results of this study with BUMELTT in patients transplanted with relapsed or persistent disease are similar to the results that have been published for other regimens used to treat relapsed or persistent advanced ovarian cancer. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] A number of different HDC regimens including BUMELTT can lead initially to high overall CR and PR rates in patients with detectable ovarian cancer. Sixty percent of the patients initially evaluated responded to the BUMELTT regimen. With other regimens, the initial response rate has been reported to be 55-75%. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] However, relapse remains a major problem in all of the studies. Long-term disease-free survival is seen in only 5-25% of all patients treated. In the BUMELTT regimen, the EFS rate for all patients was 30%, for patients with persistent disease 13% and for patients with platinum-resistant disease 11%. In 1992, an update was published of the transplant experience for ovarian cancer at 11 different centers. 10 Patients with persistent or relapsed ovarian cancer were offered a single high-dose regimen. Sixty-one patients had platinum-resistant disease. Overall, 85% of the patients achieved a clinical response, with 34% achieving a complete response (CR). Of the 37 patients with platinum-sensitive disease, 87% achieved a clinical response, with 73% a CR. However, for the whole group, the median event-free survival lasted only 6 months, with a 14% disease-free survival rate at 1 year. Recently, Stiff et al 14 have published the outcome of 100 consecutive patients transplanted for persistent or relapsed ovarian cancer using carboplatinum, mitoxantrone and cyclophosphamide with or without cyclosporine (n = 70), melphalan and mitoxantrone with or without taxol (n = 25) or other regimens (n = 5). Overall, 66% of the patients had platinum-resistant disease, 61% had у1 cm tumor burden and 70% had received two or more chemotherapy regimens prior to HDC. The median progression-free survival and OS times were 7 and 13 months for all patients and 19 and 30 months, respectively, in platinum-sensitive patients with р1 cm of disease at HDC. A stepwise Cox proportional hazards model identified tumor bulk and cisplatin sensitivity as the best predictors of progression-free survival.
As of 6 January 1995, the American Blood and Marrow Transplant Registry had 249 patients with ovarian cancer treated at 51 centers. Seventeen percent of the patients were treated with HDC in remission and 83% still had evidence of persistent disease. The 2-year probability of survival was 33% for the patients with persistent disease at HDC and 68% for the patients transplanted in clinical CR. 28 These results are similar to our results where the probabilities of survival at 18 months for patients in clinical CR when treated with BUMELTT was 0.87 and for patients not in CR 0.38 (Figures 2 and 3) .
It is clear that a single course of high-dose chemotherapy alone as used in a number of different regimens will not cure the majority of patients with platinum-resistant or persistent advanced disease. It is possible though, that those patients with platinum-sensitive disease and clinical CR prior to HDC may still benefit from being treated with an HDC regimen as their overall survival may exceed that seen with conventional chemotherapy alone.
Therefore, new approaches are needed to treat patients with advanced ovarian cancer. One approach is to offer HDC to patients in first clinical CR after surgical debulking and completion of a maximum of six cycles of platinum/taxol standard chemotherapy. HDC may be more effective if utilized earlier in the course of ovarian cancer before the emergence of chemotherapy-resistant disease and at a time of minimal tumor burden. This is suggested by the outcome of the platinum-sensitive patients in our study who have an EFS rate of 0.52 at 18 months and by the fact that five out of seven patients who were in 1st clinical CR at the time of HDC remain alive and in remission.
To date, there are few studies of HDC followed by stem cell rescue as front-line therapy for ovarian cancer. Menichella et al 29 treated 13 patients who had Ͼ0.5 cm of tumor after staging laparotomy. These patients initially received two courses of standard-dose cisplatinum and cyclophosphamide with PBSC collection. They then received a platinum-based HDC regimen. After second-look laparotomy, there were four patients who achieved a CR and five who achieved a PR. Three patients (23%) remained without evidence of disease at 108-443 days.
Viens et al 30 reported 35 patients with ovarian cancer treated with bone marrow transplantation as part of their initial therapy. After initial surgery, 30 patients with stage III and five with stage IV received a median of six cycles of a standard cisplatinum-based regimen. Following primary therapy, three had progressive disease. The rest underwent second-look laparotomy to document tumor response to initial therapy. Nine patients were in CR, 10 had Ͻ2 cm residual disease, and eight had Ͼ2 cm residual disease. Patients then received MEL (140-240 mg/m 2 ) followed by autologous bone marrow transplantation. The overall survival was 47% at 54 months. The initial response rate was 75% in the 12 patients evaluated. Of the nine individuals who at second-look laparotomy were in CR, six remain NED at 9+ to 32+ months. Of the 10 individuals with Ͻ2 cm residual disease, six are alive and NED at 13+ to 54+ months.
Recently, Legros et al 28 published the outcome of 53 stage III or IV ovarian cancer patients treated with surgery followed by cisplatin combination chemotherapy. All underwent second-look surgery. HDC was then administered. Twenty-three patients received melphalan alone, and 30 received carboplatinum/cyclosphamide. After HDC, autologous PBSC were infused. One patient died of RRT. With a median follow-up of 81.5 months, the 5-year overall survival rate of all of these 53 treated patients was 59.9% and the disease-free survival rate was 23.6%. In the 19 patients with pathological CR at second-look surgery, the 5-year survival rate was 74.2% and the DFS rate was 32.8%. Overall, the 5-year survival of these 53 patients treated with HDC appears superior to the 15-25% survival that is reported with conventional therapy. 31, 32 Of interest, HDC appeared to improve survival by delaying relapse without inducing chemoresistance to second-line cisplatin therapy. The 38 patients who relapsed after HDC had a good response to cisplatin-based therapy with an overall survival rate after relapse of 17.3 months.
In this current report, we did not treat patients who fulfilled the above definition of first clinical complete remission after six cycles of platinum combination therapy. Six of the seven patients that were in first clinical CR before BUMELTT took 7-12 cycles of chemotherapy and two to four different regimens to achieve a CR ( Table 2 ).
The trials reported by Menichella et al, 29 Viens et al 30 and Legros et al 28 suggest that HDC can be successfully incorporated into primary therapeutic strategies for treating ovarian cancer. Consequently, large prospective randomized trials of HDC as consolidation for primary induction regimens are needed to ascertain whether they will improve the poor 5-year survival rates for patients with stage III and IV ovarian cancer.
The effectiveness of treating advanced ovarian cancer with HDC remains undefined. Patients with platinum-sensitive disease appear most likely to benefit initially from a HDC regimen such as BUMELTT. However, the duration of this benefit remains to be determined. Future studies are now needed to direct HDC toward stage III/IV ovarian cancer patients in first clinical remission following standard platinum-based regimens to ascertain whether any impact can be achieved with this approach on the long-term disease-free survival of these patients. New and novel HDC regimens are needed to treat patients with persistent and platinum-resistant disease. From a number of published studies including the above study using BUMELTT, it is obvious that a single HDC regimen fails to cure the majority of these patients. As a consequence, we are offering these patients immunotherapy with IL-2 incubated PBSC and escalating doses of sequential IL-2 after completion of the BUMELTT regimen in a phase I clinical trial. We have also begun evaluating the response of patients with persistent disease to two tandem transplants using mitoxantrone/TT followed by PBSC rescue, then MEL followed by PBSC rescue and finally 12 weeks of IL-2 immunotherapy. Whether the addition of immunotherapy or tandem cycles of HDC will impact favorably on the outcome of these latter patients remains to be seen. A valid argument can still be made for pursuing treatment with a simple single HDC regimen only in patients with platinum-sensitive disease.
